Inhaled amikacin for pneumonia treatment and dissemination prevention

Motos, Ana|||0000-0002-3757-1232; Yang, Hua; Li Bassi, Gianluigi; Yang, Minlan; Meli, Andrea; Battaglini, Denise; Cabrera, Roberto; Bobi, Joaquim|||0000-0002-9026-5226; Pagliara, Francesco; Frigola, Gerard|||0000-0001-6794-6456; Camprubí-Rimblas, Marta|||0000-0002-4085-5324; Fernández Barat, Laia|||0000-0001-7528-9636; Rigol, Montserrat; Ferrer-Segarra, Antoni; Kiarostami, Kasra; Martínez Hernández, Daniel|||0000-0001-7492-5311; Nicolau, David P.; Artigas Raventós, Antoni|||0000-0002-8029-1017; Pelosi, Paolo|||0000-0001-5055-3023; Vila Estapé, Jordi|||0000-0002-8025-3926; Torres, Antoni|||0000-0002-8643-2167

Inhaled amikacin for pneumonia treatment and dissemination prevention

Pseudomonas aerugino sa pneumonia is commonly treated with systemic antibiotics to ensure adequate treatment of multidrug resistant (MDR) bacteria. However, intravenous (IV) antibiotics often achieve suboptimal pulmonary concentrations. We therefore aimed to evaluate the effect of inhaled amikacin (...

Descripción completa

Detalles Bibliográficos
Autores:	Motos, Ana\|\|\|0000-0002-3757-1232, Yang, Hua, Li Bassi, Gianluigi, Yang, Minlan, Meli, Andrea, Battaglini, Denise, Cabrera, Roberto, Bobi, Joaquim\|\|\|0000-0002-9026-5226, Pagliara, Francesco, Frigola, Gerard\|\|\|0000-0001-6794-6456, Camprubí-Rimblas, Marta\|\|\|0000-0002-4085-5324, Fernández Barat, Laia\|\|\|0000-0001-7528-9636, Rigol, Montserrat, Ferrer-Segarra, Antoni, Kiarostami, Kasra, Martínez Hernández, Daniel\|\|\|0000-0001-7492-5311, Nicolau, David P., Artigas Raventós, Antoni\|\|\|0000-0002-8029-1017, Pelosi, Paolo\|\|\|0000-0001-5055-3023, Vila Estapé, Jordi\|\|\|0000-0002-8025-3926, Torres, Antoni\|\|\|0000-0002-8643-2167
Tipo de recurso:	artículo
Fecha de publicación:	2023
País:	España
Institución:	Universitat Autònoma de Barcelona
Repositorio:	Dipòsit Digital de Documents de la UAB
Idioma:	inglés
OAI Identifier:	oai:ddd.uab.cat:273245
Acceso en línea:	https://ddd.uab.cat/record/273245 https://dx.doi.org/urn:doi:10.1186/s13054-023-04331-x
Access Level:	acceso abierto
Palabra clave:	Inhaled amikacin Severe pneumonia Pseudomonas aeruginosa Animal model Multidrug resistance Monolateral pneumonia

id	ES_3da0bd9b1e8769d7bfd783fddc57745f
oai_identifier_str	oai:ddd.uab.cat:273245
network_acronym_str	ES
network_name_str	España
repository_id_str
spelling	Inhaled amikacin for pneumonia treatment and dissemination preventionan experimental model of severe monolateral Pseudomonas aeruginosa pneumoniaMotos, Ana\|\|\|0000-0002-3757-1232Yang, HuaLi Bassi, GianluigiYang, MinlanMeli, AndreaBattaglini, DeniseCabrera, RobertoBobi, Joaquim\|\|\|0000-0002-9026-5226Pagliara, FrancescoFrigola, Gerard\|\|\|0000-0001-6794-6456Camprubí-Rimblas, Marta\|\|\|0000-0002-4085-5324Fernández Barat, Laia\|\|\|0000-0001-7528-9636Rigol, MontserratFerrer-Segarra, AntoniKiarostami, KasraMartínez Hernández, Daniel\|\|\|0000-0001-7492-5311Nicolau, David P.Artigas Raventós, Antoni\|\|\|0000-0002-8029-1017Pelosi, Paolo\|\|\|0000-0001-5055-3023Vila Estapé, Jordi\|\|\|0000-0002-8025-3926Torres, Antoni\|\|\|0000-0002-8643-2167Inhaled amikacinSevere pneumoniaPseudomonas aeruginosaAnimal modelMultidrug resistanceMonolateral pneumoniaPseudomonas aerugino sa pneumonia is commonly treated with systemic antibiotics to ensure adequate treatment of multidrug resistant (MDR) bacteria. However, intravenous (IV) antibiotics often achieve suboptimal pulmonary concentrations. We therefore aimed to evaluate the effect of inhaled amikacin (AMK) plus IV meropenem (MEM) on bactericidal efficacy in a swine model of monolateral MDR P. aeruginosa pneumonia. We ventilated 18 pigs with monolateral MDR P. aeruginosa pneumonia for up to 102 h. At 24 h after the bacterial challenge, the animals were randomized to receive 72 h of treatment with either inhaled saline (control), IV MEM only, or IV-MEM plus inhaled AMK (MEM + AMK). We dosed IV MEM at 25 mg/kg every 8 h and inhaled AMK at 400 mg every 12 h. The primary outcomes were the P. aeruginosa burden and histopathological injury in lung tissue. Secondary outcomes included the P. aeruginosa burden in tracheal secretions and bronchoalveolar lavage fluid, the development of antibiotic resistance, the antibiotic distribution, and the levels of inflammatory markers. The median (25-75th percentile) P. aeruginosa lung burden for animals in the control, MEM only, and MEM + AMK groups was 2.91 (1.75-5.69), 0.72 (0.12-3.35), and 0.90 (0-4.55) log CFU/g (p = 0.009). Inhaled therapy had no effect on preventing dissemination compared to systemic monotherapy, but it did have significantly higher bactericidal efficacy in tracheal secretions only. Remarkably, the minimum inhibitory concentration of MEM increased to.Universitat Autònoma de Barcelona 22023-01-0120232023-01-01Articlehttp://purl.org/coar/resource_type/c_6501VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://ddd.uab.cat/record/273245https://dx.doi.org/urn:doi:10.1186/s13054-023-04331-xreponame:Dipòsit Digital de Documents de la UABinstname:Universitat Autònoma de BarcelonaInglésengMinisterio de Sanidad y Consumo CB06/06/0028Fundació la Marató de TV3 https://doi.org/10.13039/100008666 201831-10open accesshttp://purl.org/coar/access_right/c_abf2Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.https://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:ddd.uab.cat:2732452026-06-06T12:50:31Z
dc.title.none.fl_str_mv	Inhaled amikacin for pneumonia treatment and dissemination prevention an experimental model of severe monolateral Pseudomonas aeruginosa pneumonia
title	Inhaled amikacin for pneumonia treatment and dissemination prevention
spellingShingle	Inhaled amikacin for pneumonia treatment and dissemination prevention Motos, Ana\|\|\|0000-0002-3757-1232 Inhaled amikacin Severe pneumonia Pseudomonas aeruginosa Animal model Multidrug resistance Monolateral pneumonia
title_short	Inhaled amikacin for pneumonia treatment and dissemination prevention
title_full	Inhaled amikacin for pneumonia treatment and dissemination prevention
title_fullStr	Inhaled amikacin for pneumonia treatment and dissemination prevention
title_full_unstemmed	Inhaled amikacin for pneumonia treatment and dissemination prevention
title_sort	Inhaled amikacin for pneumonia treatment and dissemination prevention
dc.creator.none.fl_str_mv	Motos, Ana\|\|\|0000-0002-3757-1232 Yang, Hua Li Bassi, Gianluigi Yang, Minlan Meli, Andrea Battaglini, Denise Cabrera, Roberto Bobi, Joaquim\|\|\|0000-0002-9026-5226 Pagliara, Francesco Frigola, Gerard\|\|\|0000-0001-6794-6456 Camprubí-Rimblas, Marta\|\|\|0000-0002-4085-5324 Fernández Barat, Laia\|\|\|0000-0001-7528-9636 Rigol, Montserrat Ferrer-Segarra, Antoni Kiarostami, Kasra Martínez Hernández, Daniel\|\|\|0000-0001-7492-5311 Nicolau, David P. Artigas Raventós, Antoni\|\|\|0000-0002-8029-1017 Pelosi, Paolo\|\|\|0000-0001-5055-3023 Vila Estapé, Jordi\|\|\|0000-0002-8025-3926 Torres, Antoni\|\|\|0000-0002-8643-2167
author	Motos, Ana\|\|\|0000-0002-3757-1232
author_facet	Motos, Ana\|\|\|0000-0002-3757-1232 Yang, Hua Li Bassi, Gianluigi Yang, Minlan Meli, Andrea Battaglini, Denise Cabrera, Roberto Bobi, Joaquim\|\|\|0000-0002-9026-5226 Pagliara, Francesco Frigola, Gerard\|\|\|0000-0001-6794-6456 Camprubí-Rimblas, Marta\|\|\|0000-0002-4085-5324 Fernández Barat, Laia\|\|\|0000-0001-7528-9636 Rigol, Montserrat Ferrer-Segarra, Antoni Kiarostami, Kasra Martínez Hernández, Daniel\|\|\|0000-0001-7492-5311 Nicolau, David P. Artigas Raventós, Antoni\|\|\|0000-0002-8029-1017 Pelosi, Paolo\|\|\|0000-0001-5055-3023 Vila Estapé, Jordi\|\|\|0000-0002-8025-3926 Torres, Antoni\|\|\|0000-0002-8643-2167
author_role	author
author2	Yang, Hua Li Bassi, Gianluigi Yang, Minlan Meli, Andrea Battaglini, Denise Cabrera, Roberto Bobi, Joaquim\|\|\|0000-0002-9026-5226 Pagliara, Francesco Frigola, Gerard\|\|\|0000-0001-6794-6456 Camprubí-Rimblas, Marta\|\|\|0000-0002-4085-5324 Fernández Barat, Laia\|\|\|0000-0001-7528-9636 Rigol, Montserrat Ferrer-Segarra, Antoni Kiarostami, Kasra Martínez Hernández, Daniel\|\|\|0000-0001-7492-5311 Nicolau, David P. Artigas Raventós, Antoni\|\|\|0000-0002-8029-1017 Pelosi, Paolo\|\|\|0000-0001-5055-3023 Vila Estapé, Jordi\|\|\|0000-0002-8025-3926 Torres, Antoni\|\|\|0000-0002-8643-2167
author2_role	author author author author author author author author author author author author author author author author author author author author
dc.contributor.none.fl_str_mv	Universitat Autònoma de Barcelona
dc.subject.none.fl_str_mv	Inhaled amikacin Severe pneumonia Pseudomonas aeruginosa Animal model Multidrug resistance Monolateral pneumonia
topic	Inhaled amikacin Severe pneumonia Pseudomonas aeruginosa Animal model Multidrug resistance Monolateral pneumonia
description	Pseudomonas aerugino sa pneumonia is commonly treated with systemic antibiotics to ensure adequate treatment of multidrug resistant (MDR) bacteria. However, intravenous (IV) antibiotics often achieve suboptimal pulmonary concentrations. We therefore aimed to evaluate the effect of inhaled amikacin (AMK) plus IV meropenem (MEM) on bactericidal efficacy in a swine model of monolateral MDR P. aeruginosa pneumonia. We ventilated 18 pigs with monolateral MDR P. aeruginosa pneumonia for up to 102 h. At 24 h after the bacterial challenge, the animals were randomized to receive 72 h of treatment with either inhaled saline (control), IV MEM only, or IV-MEM plus inhaled AMK (MEM + AMK). We dosed IV MEM at 25 mg/kg every 8 h and inhaled AMK at 400 mg every 12 h. The primary outcomes were the P. aeruginosa burden and histopathological injury in lung tissue. Secondary outcomes included the P. aeruginosa burden in tracheal secretions and bronchoalveolar lavage fluid, the development of antibiotic resistance, the antibiotic distribution, and the levels of inflammatory markers. The median (25-75th percentile) P. aeruginosa lung burden for animals in the control, MEM only, and MEM + AMK groups was 2.91 (1.75-5.69), 0.72 (0.12-3.35), and 0.90 (0-4.55) log CFU/g (p = 0.009). Inhaled therapy had no effect on preventing dissemination compared to systemic monotherapy, but it did have significantly higher bactericidal efficacy in tracheal secretions only. Remarkably, the minimum inhibitory concentration of MEM increased to.
publishDate	2023
dc.date.none.fl_str_mv	2 2023-01-01 2023 2023-01-01
dc.type.none.fl_str_mv	Article http://purl.org/coar/resource_type/c_6501 VoR http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv	info:eu-repo/semantics/article
format	article
dc.identifier.none.fl_str_mv	https://ddd.uab.cat/record/273245 https://dx.doi.org/urn:doi:10.1186/s13054-023-04331-x
url	https://ddd.uab.cat/record/273245 https://dx.doi.org/urn:doi:10.1186/s13054-023-04331-x
dc.language.none.fl_str_mv	Inglés eng
language_invalid_str_mv	Inglés
language	eng
dc.relation.none.fl_str_mv	Ministerio de Sanidad y Consumo CB06/06/0028 Fundació la Marató de TV3 https://doi.org/10.13039/100008666 201831-10
dc.rights.none.fl_str_mv	open access http://purl.org/coar/access_right/c_abf2 https://creativecommons.org/licenses/by/4.0/
dc.rights.openaire.fl_str_mv	info:eu-repo/semantics/openAccess
rights_invalid_str_mv	open access http://purl.org/coar/access_right/c_abf2 https://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv	openAccess
dc.format.none.fl_str_mv	application/pdf
dc.source.none.fl_str_mv	reponame:Dipòsit Digital de Documents de la UAB instname:Universitat Autònoma de Barcelona
instname_str	Universitat Autònoma de Barcelona
reponame_str	Dipòsit Digital de Documents de la UAB
collection	Dipòsit Digital de Documents de la UAB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_	1869406459263975424
score	15,300719

Inhaled amikacin for pneumonia treatment and dissemination prevention

Similares en LA Referencia